Datroway (datopotamab deruxtecan) has become the first oncology drug to significantly improve overall survival compared to chemotherapy in an aggressive form of invasive breast cancer.
Datroway (datopotamab deruxtecan) has become the first oncology drug to significantly improve overall survival compared to chemotherapy in an aggressive form of invasive breast cancer.